Barclays PLC cut its stake in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 95.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,000 shares of the company's stock after selling 70,352 shares during the quarter. Barclays PLC's holdings in Novo Nordisk A/S were worth $299,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Csenge Advisory Group lifted its position in shares of Novo Nordisk A/S by 3.9% during the third quarter. Csenge Advisory Group now owns 2,542 shares of the company's stock worth $253,000 after purchasing an additional 95 shares during the last quarter. Advisory Research Inc. lifted its position in shares of Novo Nordisk A/S by 4.1% during the second quarter. Advisory Research Inc. now owns 2,462 shares of the company's stock worth $274,000 after purchasing an additional 97 shares during the last quarter. Private Ocean LLC lifted its position in shares of Novo Nordisk A/S by 9.1% during the third quarter. Private Ocean LLC now owns 1,255 shares of the company's stock worth $125,000 after purchasing an additional 105 shares during the last quarter. Roundview Capital LLC lifted its position in shares of Novo Nordisk A/S by 0.6% during the first quarter. Roundview Capital LLC now owns 18,803 shares of the company's stock worth $2,088,000 after purchasing an additional 106 shares during the last quarter. Finally, Davis R M Inc. lifted its position in shares of Novo Nordisk A/S by 2.7% during the second quarter. Davis R M Inc. now owns 4,262 shares of the company's stock worth $475,000 after purchasing an additional 112 shares during the last quarter. 6.09% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 1.4 %

NVO opened at $140.96 on Thursday. The business has a 50 day simple moving average of $136.28 and a 200-day simple moving average of $118.17. The stock has a market capitalization of $318.99 billion, a P/E ratio of 40.62, a P/E/G ratio of 1.83 and a beta of 0.49. Novo Nordisk A/S has a 12 month low of $94.75 and a 12 month high of $144.78. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.89 and a quick ratio of 0.69.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 4th. Investors of record on Monday, March 27th will be paid a $1.1887 dividend. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.58. The ex-dividend date of this dividend is Friday, March 24th. This represents a dividend yield of 0.8%. Novo Nordisk A/S's payout ratio is 23.34%.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Cowen lifted their target price on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. Cowen raised their price target on Novo Nordisk A/S from $130.00 to $145.00 in a research note on Monday, December 12th. Credit Suisse Group raised their price target on Novo Nordisk A/S from 820.00 to 860.00 in a research note on Friday, November 4th. Finally, JPMorgan Chase & Co. raised their price target on Novo Nordisk A/S from 925.00 to 1,100.00 and gave the company an "overweight" rating in a research note on Tuesday, January 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $697.78.

Novo Nordisk A/S Company Profile

(Get Rating)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.

Further Reading

• Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
• Roblox Gains Traction With Metaverse, Shares Pop
• GXO Logistics Manages Another Buying Opportunity
• Arista Networks In Buy Range After Topping Q4 Views
• Analysts Like The Flavor Of Restaurant Brands International
• What is Consumer Discretionary?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Get Rating).

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.